| ²é¿´: 753 | »Ø¸´: 5 | ||||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||||
[½»Á÷]
°ïæ¿´¿´ÓйØÑо¿µ°°×ÖÊÏ໥×÷ÓõķÖÎö·½·¨ÎÊÌâ
|
||||
|
Ê×ÏÈÉùÃ÷£¬±¾È˲»¶®ÉúÎïѧ£¬ËùÒÔÎÄÏ×ÖÐÓйØÊµÑé·½·¨µÄÆðʼ¾ä²»Ì«Ã÷°×¡£ 1To determine whether the compounds inhibited bromodomain-histone binding we utilized a peptide displacement assay based on AlphaScreen technology. Õâ¾ä»°ÖУ¬Ö÷ÒªÊDzÉÓá°Ê²Ã´·½·¨£¿ÉúÎïµÄ²»¶®£¬Çë¸øÓë½âÊÍ¡±²â¶¨»¯ºÏÎïÒÖÖÆäåÓòµ°°×-×é°±ËáµÄ½áºÏ×÷Óᣠ2 to investigate the selectivity of these compounds against other bromodomain, we employed a binding assay based on protein stablity shift. Õâ¾ä»°£¬ÒÀ¾ÉÊǺó°ë¾ä£¬ÉúÎïѧµÄ·ÖÎö·½·¨£¬²»¶®£¬ÐèÒª¸÷λ°ïÎÒɨä¡£ 3 To order to confirm that the dimethylisoxazole moiety was acting as a KAc minic and to elucidate structure-activity profiles for these compounds , we obtained the cocrystal structures of -------. Õâ¾ä»°¾ÍÊÇKAcÊÇɶËõд°¡¡£ ÁíÍ⣬ÓйضԵ°°×ÒÖÖÆ×÷ÓõÄ×ø±êͼÖУ¬ Y-×ø±ê£¨RLUs£©ºÍX-×ø±ê(Dose)·Ö±ð´ú±íʲôº¬Ò壬ͼÌù²»ÉÏÈ¥°¡¡£ |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
·Ö×ÓÉú»¯ÊµÑé¾Ñé»ýÀÛ |
» ²ÂÄãϲ»¶
µ°°×Öʼì²â£º¾«×¼·ÖÎö£¬½âËøÉúÎï·Ö×ÓµÄÃÜÂë
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑé֮СÊóʵÑ飺ÑϽ÷Éè¼Æ£¬½âÎöÉúÃü»úÖÆµÄÖØÒªÔØÌå
ÒѾÓÐ0È˻ظ´
»¯Ñ§¹¤³Ì¼°¹¤Òµ»¯Ñ§ÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ162È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®ÖØ½ðÊô¼ì²â£º¾«×¼É¸²é£¬ÊØ»¤½¡¿µÓë»·¾³µÄ·ÀÏß
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®¡°ÍܲâÖØ½ðÊôÎÒ±³¹øÈýǧ¡±
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®¡°ÊóÌÓÈý´ÎÎÒ·¢ÈýƪSCI¡±
ÒѾÓÐ0È˻ظ´
ÄÉÃ×Á£¶È·ÖÎö
ÒѾÓÐ3È˻ظ´
ÁÖ¿ÆÔºÁÖ»¯ËùÕÐÊÕ²ÄÁÏÓ뻯¹¤×¨ÒµË¶Ê¿£¬×ø±êÄϾ©
ÒѾÓÐ0È˻ظ´
Áôѧ--²©Ê¿ÕÐÉú
ÒѾÓÐ15È˻ظ´
»¯Ñ§¹¤³Ì£¬±¾211£¬Çóµ÷¼Á£¬abÇø²»ÏÞ
ÒѾÓÐ4È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
µ°°×ÖÊÖ®¼äÏ໥×÷ÓõÄÑо¿·½·¨ÓÐÄÄЩ£¿
ÒѾÓÐ3È˻ظ´
ÄÄλ°ï°ïæ°¡£¿¹ØÓÚµ°°×µÄÎÊÌâ
ÒѾÓÐ5È˻ظ´
Çë´ó¼Ò°ïæ¿´¿´Îҵĵ°°×µçӾͼ£¬Ð»Ð»´ó¼ÒÁË
ÒѾÓÐ10È˻ظ´
ϸ°ûÄÚµ°°×ÖʵÄÇ×ÊèË®ÐÔµÄÎÊÌ⣬´ó¼ÒÀ´°ïæ¿´¿´¡£
ÒѾÓÐ7È˻ظ´
Ô²¶þÉ«Æ×¶Ô·ÖÎöµ°°×ÖÊÏ໥×÷ÓÃÓаïÖúÂð
ÒѾÓÐ5È˻ظ´
¹ØÓÚE-tag±ê¼Çµ°°×µÄ´¿»¯ÎÊÌ⣡~ÇóÖú£¬Ð»Ð»°ïæ~£¡
ÒѾÓÐ9È˻ظ´
´óϺÃǰïæ¿´¿´3ºÍ4ÕâÁ½¸öµ°°×ÓÃʲôÑùµÄÖù×ÓÌîÁÏÄÜ·Ö¿ª
ÒѾÓÐ10È˻ظ´
°ïæ¿´¿´Éó¸åÒâ¼û£ºÓйطÖ×Ó¶¯Á¦Ñ§Ä£Äâ½âÊ͵°°×Óëµ×ÎïÏ໥×÷ÓÃ
ÒѾÓÐ3È˻ظ´
µ°°×ÖÊÏ໥×÷Óã¿
ÒѾÓÐ4È˻ظ´
´ó¼Ò°ïæ·ÖÎöÒ»ÏÂÎҵĵ°°×´¿»¯Ê±³öÏÖµÄÎÊÌâ°É£¬²»Ê¤¸Ð¼¤
ÒѾÓÐ5È˻ظ´
Çóµ°°×ÖÊÏ໥×÷ÓÃÑо¿·½·¨...
ÒѾÓÐ12È˻ظ´
µ°°×²¹²Ð»ù£¬¸÷λ°ï°ï濴ϰ¡£¡
ÒѾÓÐ11È˻ظ´
¡¾ÇóÖú¡¿¼¦µ°µÄµ°°×ÖÊŨ¶ÈÎÊÌ⣡£¡¸÷λ´óÏÀÇë°ï棡£¡
ÒѾÓÐ3È˻ظ´
¡¾ÇóÖú/½»Á÷¡¿¹ØÓÚQÖù·ÖÀëµ°°×µÄÎÊÌâ~¸ßÊÖ°ï°ïæ~
ÒѾÓÐ7È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
±¾×ÓÖÕÓÚÌá½»ÁË¡£²»ÓÃÔÙ¿´ÁË£¬Ò»ÇÐÏÐÏÂÀ´ÂýÂýµÈ¡£Ï£ÍûÒ»ÇÐ˳Àû£¡
+1/629
ÄϾ©Ò½¿Æ´óѧÉúֳҽѧÓë×Ó´ú½¡¿µ¹úÖØÊµÑéÊÒ-¶·Éºê¿ÎÌâ×é-2026Ä격ʿÕÐÉú-9ÔÂÈëѧ
+1/82
ÉϺ£´óѧ ¡°ÉúÎïÓлúµç×Ó²ÄÁϼ°Æ÷¼þ¡±ÍŶÓ˶ʿ¡¢²©Ê¿Ñо¿ÉúÕÐÆ¸
+1/38
2026Éèʩ԰ÒÕ×÷Îï»·¾³µ÷¿ØÓëÂÌÉ«Éú²úÍŶÓÕÐÊÕÏà¹Ø×¨Òµµ÷¼ÁÑо¿Éú
+1/34
ÕÐÊÕ2026Äê²ÄÁÏÓ뻯¹¤×¨Ë¶µ÷¼Á£¬É½¶«Ê¡ÊôÖØµã´óѧ£¬¹ý¹ú¼ÒÏß¼´¿Éµ÷¼Á£¬Ãû¶î³ä×ã
+2/32
Ìì½òÀí¹¤´óѧ¹ú¼Ò½ÜÇàÍõÌúÍŶÓÕÐÆ¸
+1/30
ͬ¼Ã´óѧ»·¾³Ñ§Ôº Ð¤Ù»ÌØÆ¸Ñо¿Ô±¿ÎÌâ×é ÕÐÆ¸Ë¶Ê¿/²©Ê¿£¨³¤ÆÚÓÐЧ£©
+1/17
ÏÂÖܼûÒ»¸öºÏ×÷Õߣ¬Ó¦¸ÃÎÊЩʲô
+1/16
³ÏÖ¿ÕÐÉú£¨Ë¶Ê¿+²©Ê¿£©
+1/9
shuÏæÌ¶´óѧ»¯¹¤Ñ§ÔºÕÐÊÕ»¯¹¤¡¢ÄÜÔ´¶¯Á¦¡¢¹¤³ÌÈÈÎïÀíÏà¹ØÑо¿Éúµ÷¼Á
+1/8
ÄϾ©ÁÖÒµ´óѧ»¯Ñ§¹¤³ÌѧԺ°ØÐÊ·å¿ÎÌâ×é³ÏƸ¿ÆÑÐÖúÀí¡¢Ë®É¼Ó¢²ÅEÀà/FÀàÇàÄê½Ìʦ»ò²©ºó
+1/7
2026ÄêÖйú¿ÆÑ§Ôº³ÇÊл·¾³ËùÓ븣½¨Å©ÁÖ´óѧÁªºÏÅàÑøË¶Ê¿Ñо¿ÉúÏîÄ¿½éÉÜ
+1/6
ѰÕÒ26²©Ê¿Éúµ¼Ê¦
+1/6
¹þ¶û±õ¹¤Òµ´óѧ(ÉîÛÚ)¹ú¼Ò¼¶ÇàÄêÈ˲Żúе¹¤³Ì¡¢ÈÈÄÜÓëÄÜÔ´µÈרҵ26ÄêÈëѧ²©Ê¿ÕÐÉú
+1/5
¡¾²©Ê¿ÕÐÉú¡¿ÉϺ£½»Í¨´óѧ³ÂÙ»èÝ¿ÎÌâ×éÕÐÊÕ2026ÄêÉêÇë-¿¼ºË²©Ê¿Éú1Ãû£¨ÄÜÔ´²ÄÁÏ·½Ïò£©
+1/5
ÉϺ£Ê¦·¶´óѧ»¯Ñ§Óë²ÄÁÏ¿ÆÑ§Ñ§ÔºÈÎÐÂÒ⸱Ñо¿Ô±ÕÐÊÕµ÷¼ÁѧÉú3-4Ãû£¨Óлú»¯Ñ§×¨Òµ£©
+1/5
±±¾©¸ßУ¸±Ð£³¤ÍŶÓÕÐÊÕ»úеÀ࣬»·¾³Ààѧ˶ºÍר˶
+1/5
Öйú¿Æ´ó·ÂÉú½çÃæ²ÄÁÏ¿ÆÑ§È«¹úÖØµãʵÑéÊÒÕÅÕñ½ÌÊÚ/½À×Ժʿ³ÏƸ²©Ê¿ºó
+1/3
º£ÄÏʦ·¶´óѧ ËïÔªÔªÀÏʦÍŶÓÕÐ2026¼¶Ë¶Ê¿Éú2Ãû
+1/2
ÖйúÈËÃñ´óѧÎïÀíѧϵ²ÌÅô¿ÎÌâ×éÕÐÊÕÓÅÐã˶ʿ²©Ê¿Ñо¿Éú
+1/1
¡ï ¡ï ¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
cz_rubygd: ½ð±Ò+2, лл£¡Âé·³½üÁ½Ìì¹Ø×¢ÎÒÔÚÉúÎï°å¿éµÄÆäËûÇóÖúÌû£¬¹ØÓÚ·Ö×Ó¶Ô½ÓµÄ 2013-01-07 13:09:30
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
cz_rubygd: ½ð±Ò+2, лл£¡Âé·³½üÁ½Ìì¹Ø×¢ÎÒÔÚÉúÎï°å¿éµÄÆäËûÇóÖúÌû£¬¹ØÓÚ·Ö×Ó¶Ô½ÓµÄ 2013-01-07 13:09:30
| KAc, ÄãµÃ¿´¿´ÎÄÖÐÊÇ·ñÏà·û¡£ÎÒ¸øÄãµÄÎÄÏ×ÓÐһƪ¾ÍÊÇ×östability shift¡£ ÀýÈ磬ÄãÓÃÈȱäÐÔÀ´¿¼²ìµ°°×Îȶ¨ÐÔ£¬ ÓÉÓÚÌõ¼þµÄ¸Ä±ä£¬¼Óµ×Î µÃµ½µÄÇúÏßÓëÎÞµ×ÎïµÄ¾Í²»Ò»Ö¡£Õâ¾ÍÊÇÎȶ¨ÐÔÆ¯ÒÆ£¡ |
4Â¥2013-01-07 09:03:57
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
cz_rubygd: ½ð±Ò+4, лл£¬protein stablity shiftÊÇʲôÇé¿ö£¿ 2013-01-06 22:54:33
Сµ¤Ä¾Ä¾: ½ð±Ò+3, ¹ÄÀø½»Á÷ 2013-01-07 16:30:31
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
cz_rubygd: ½ð±Ò+4, лл£¬protein stablity shiftÊÇʲôÇé¿ö£¿ 2013-01-06 22:54:33
Сµ¤Ä¾Ä¾: ½ð±Ò+3, ¹ÄÀø½»Á÷ 2013-01-07 16:30:31
|
ÄãÕâÆªÎÄÕµÄʵÑéÐԷdz£Ç¿£¬ÓеãÏñС×ÛÊö¡£Éæ¼°µÄ¼¼Êõ½Ï¶à£¬ 1. alpha Screen: http://www.proteomebinders.org/meetings/alpbach/talks/Chevet.pdf 2.A bromodomain is a protein domain that recognizes acetylated lysine residues such as those on the N-terminal tails of histonesËùÒÔÊDzⶨ»¯ºÏÎï¶ÔBromodomain»îÐÔµÄÒÖÖÆ×÷Óà 3.ÕâÊÇÑо¿µ°°×½á¹¹ÐÔÖʵķ½·¨£¬¿ÉÒÔÔĶÁ±¾ÎÄhttp://www.ncbi.nlm.nih.gov/pubmed/21674662 4.µÚÈýµã£¬°®ÄªÄÜÖú£¬Ëõд̫¶à£¬¶øÇÒûͼ²»ÄÜÅÐ¶Ï |
2Â¥2013-01-06 14:15:04
ccharlien
ľ³æ (ÕýʽдÊÖ)
- MolEPI: 1
- Ó¦Öú: 82 (³õÖÐÉú)
- ½ð±Ò: 2630.1
- Ìû×Ó: 334
- ÔÚÏß: 180.3Сʱ
- ³æºÅ: 1168776
¡ï ¡ï ¡ï ¡ï ¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
cz_rubygd: ½ð±Ò+2, лл 2013-01-06 22:54:27
Сµ¤Ä¾Ä¾: ½ð±Ò+2, ¹ÄÀø½»Á÷ 2013-01-07 16:30:47
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
cz_rubygd: ½ð±Ò+2, лл 2013-01-06 22:54:27
Сµ¤Ä¾Ä¾: ½ð±Ò+2, ¹ÄÀø½»Á÷ 2013-01-07 16:30:47
|
3. ʵÑéÊÒÀïKAc Ò»°ãÊÇ´×Ëá¼ØµÄËõд£¨Potassium acetate£©£¬Ã»ÓÐÉÏÏÂÎÄ£¬²»È·¶¨ RLUsÒ»°ãÊÇRelative Luciferase UnitsµÄËõд Dose¾ÍÊÇÊÔ¼ÁµÄ¼ÁÁ¿ ¿´ÆðÀ´ÊÇÓÃÁËÒ»¸ö±¨¸æ»ùÒòÊÔÑéÖ¤Ã÷¼ÁÁ¿¶Ô»îÐԸıäµÄÓ°Ïì |
3Â¥2013-01-06 20:57:27
5Â¥2013-01-07 12:48:27













»Ø¸´´ËÂ¥